Basics and New Frontiers of MR Spectroscopy with High Tesla

Burtscher IM Hollas S – Proton MR spectroscopy in clinical routine. J Magn Reson Imaging 13:560–567, 2001.

Danielsen ER Ross B - Magnetic resonance spectroscopy diagnosis of neurological disease. New York. Marcel Dekker, 1999.

Hethcrington HP Mason GF Pan JW Ponder SL Vaughan JT Tweig DB Pohost GM – Evaluation of cerebral gray and white matter metabolite differences by spectroscopic imaging at 4. 1T. Magn Reson Med 32:565–571, 1994.

Burtscher IM Holtas S – Proton magnetic resonance spectroscopy in brain tumours: clinical applications. Neuroradiology 43:345–352, 2001.

Hunter JW Wang ZJ - MR spectroscopy in pediatric Neuroradiology - Pediatric MR neuroimaging, 9:165–189, 2001.

Gonen O Grossman RI – The accuracy of whole brain N -acetylaspartate quantification. Magn Reson Imag 18:1255–1258, 2000.

Huppi PS . – MR imaging and spectroscopy of brain development. Pediatric MR neuroimaging, 9:1–17, 2001.

Tamiya T Kinoshita K Ono Y Matsumoto K Furuta T Ohmoto T – Proton magnetic resonance spectroscopy reflects cellular proliferative activity in astrocytomas. Neuroradiology 42:333–338, 2000.

Yang D Korogi Y Sugahara T Kitajima M. Shigematsu Y Liang L Ushio Y Takahashi M – Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI. Neuroradiology 44:656–666, 2002.

Burtschcr IM Skagerberg G Geijer B Englund E Stahlberg F Holtas S – Proton MR spectroscopy and preoperative diagnostic accuracy: an evaluation of intracranial mass lesions characterized by stereotactic biopsy findings. AJNR 21:84–93, 2002.

Burtscher IM Holtas S – In vivo 1H-MR spectroscopy in untreated and treated brain abscesses. AJNR 20:1049–1053, 1999.

Schlemmer HP Bachert P Herfarth KK Zuna I Debus J van Kaick G – Proton MR spectroscopy evaluation of suspicious brain lesions after stereotactic radiothcraphy. AJNR Am J Neuroradiol 22:1316–1324, 2001.

Fu L Matthews PM De Stefano N – Imaging axonal damage of normal appearing white matter in multiple sclerosis. Brain 121:103–113, 1998.

Vaughan JT Garwood M Collins CM Liu W DelaBarre L Adriany G Andersen P Merkle H Goebel R Smith MB Ugurbil K 7T vs 4T: RF power, homogeneity, and signal-to-noise Comparison in Head Images. Magn Reson Med 46:24–30, 2001.

Thulbom KR – Clinical rationale for very-high-field (3.0 Tesla) functional magnetic resonance imaging. Top Magn Reson Imaging 10:37–50, 1999.

Gonen O Gruger S Belinda L Mlynarik V Moser E – Multivoxel 3D proton spectroscopy in the brain at 1.5 versus 3.0T: Signal-to-ratio and resolution comparison. AJNR 22:1727–1731, 2001.

Barker PB Hearshen DO Boska MD – Single-Voxel Proton MRS of the Human Brain at 1.5T and 3.0T. Magn Reson Med 45:765–769, 2001.

Gruetter R Weisdorf SA Rajanayagan V – Resolution improvements in vivo ¹H NMR spectra with increased magnetic field strength. J. Magn. Reson 135:260–264, 1998.

Bartha R Drost DJ Menon R Williamson PC – Comparison of quantification precision of human short echo time ¹H spectroscopy at 1.5 and 4.0 Tesla. Magn Reson Med 44:185–192, 1998.

Tkac I Andersen P Adriany G Merkle H Ugurbil K Gruetter R – In vivo ¹H NMR spectroscopy of the human brain at 7T. Magn Reson Med 46:451–456, 2001.

Gruetter R Garwood M Ugurbil K Seaquist ER – Observation of resolved glucose signals in ¹H NMR spectra of the human brain at 4 Tesla. MRM 36:1–6, 1996.

Belinda L Regal J Gonen O – SNR versus resolution in 3D H-MRS of the human brain at high magnetic fields. Magn Reson Med 46:1049–1053, 2001.

P Takahashi M Uematsu H Hatabu H – MR imaging at high magnetic fields. Eur J Radiol 46:45–52, 2003.

Guidance for significant risk investigations. US CDRH, FDA, DHHS. September 29, 1997)

McKnight TR Noworolski SM Vigneron DB Nelson SJ – An automated technique for the quantitative assessment of 3D-MRSI data from patients with glioma. J Magn Reson 13:167–177, 2001.